SNCA irna formulations and methods of use thereof

TW202635320APending Publication Date: 2026-09-01ALNYLAM PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114139782
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-16
Filing Date
2025-10-15
Publication Date
2026-09-01

Smart Images

  • Figure TWG2TA001074384_001
    Figure TWG2TA001074384_001
  • Figure TWG2TA001074384_002
    Figure TWG2TA001074384_002
  • Figure TWG2TA001074384_003
    Figure TWG2TA001074384_003
Patent Text Reader

Abstract

The disclosure relates to formulations of double stranded ribonucleic acid (dsRNAi) agents targeting a SNCA gene, as well as methods of inhibiting expression of a SNCA gene and methods of treating subjects having a SNCA-associated neurodegenerative disease or disorder, e.g., Parkinson’s Disease (PD), multiple system atrophy, Lewy body dementia (LBD), among other synucleinopathies, using such dsRNAi agents formulations.
Need to check novelty before this filing date? Find Prior Art